Giving Isatuximab Before and After Autologous Stem Cell Transplant in Patients with Multiple Myeloma or Lymphoma

Inclusion Criteria

• Following diagnoses are eligible for inclusion in the study: * Multiple myeloma with ASCT used as consolidation after first line induction therapy or at first relapse * Relapsed/Refractory Hodgkin’s disease * Non-Hodgkin’s lymphomas as follows ** Relapsed/Refractory diffuse large B cell lymphoma* ** Relapsed/Refractory indolent or relapsed/refractory transformed indolent B cell lymphomas as consolidation after second line therapy ** Mantle Cell lymphoma as consolidation after first-line therapy ** Peripheral T cell lymphoma as consolidation after first-line therapy or at relapse or primary refractory disease
• Patients undergoing first ASCT will be eligible for the study. Patient who have received prior ASCT will be excluded
• Any prior therapy for the malignancy except CD38 antibody within the last 12 months is allowed
• Age >= 18 years
• Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)
• Life expectancy of greater than 6 months
• Leukocytes >= 3,000/mcL
• Absolute neutrophil count >= 1,000/mcL
• Platelets >= 50,000/mcL
• Total bilirubin within normal institutional limits
• Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 × institutional upper limit of normal
• Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria

• Previous exposure to a CD38 antibody during the last 12 months
• Participants who are receiving any other investigational agents concurrently or received any investigational agent within the last 8 weeks
• History of severe allergic reactions or anaphylaxis attributed to compounds of similar chemical or biologic composition to isatuximab
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• Pregnant and lactating women are excluded from this study because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with isatuximab. Females of childbearing potential (FCBP) must have a negative baseline pregnancy test within 14 days prior to registration. This may be either a serum or urine pregnancy test, with a sensitivity of at least 50 mIU/mL. FCBP must also agree to have a pregnancy test prior to the start of each treatment cycle. FCBP or male subjects with female partners of childbearing potential shall be required to use highly effective contraceptive methods (a failure of < 1% per year when used consistently and correctly) starting 2 weeks before first isatuximab administration, while on therapy and for 5 months following the last dose of isatuximab. A woman is considered of childbearing potential, i.e. fertile, following menarche and until becoming post- menopausal unless permanently sterile. The following highly effective methods of contraception are accepted: * Oral, intravaginal, or transdermal hormonal contraception associated with inhibition of ovulation * Placement of an intrauterine device or intrauterine hormone-releasing system * Bilateral tubal ligation, Hysterectomy or bilateral oophorectomy * Sexual abstinence during the entire period of risk associated with study treatments Men must agree to use a condom with either cap, diaphragm or sponge with spermicide (double barrier method) during sexual contact with a FCBP, even if they have had a successful vasectomy starting 2 weeks before first isatuximab administration, while on therapy and for 5 months following the last dose of isatuximab
• Human immunodeficiency virus (HIV)-positive participants are ineligible because of increased risk of lethal infections when treated with immunosuppressive therapy
• Following histologies of diffuse large B cell lymphoma are allowed for inclusion * Diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) ** Germinal center B-cell type * Activated B-cell type * T-cell/histiocyte-rich large B-cell lymphoma * Primary cutaneous DLBCL, leg type * Epstein Barr virus positive (EBV+ve) DLBCL, NOS * Primary mediastinal (thymic) large B-cell lymphoma * ALK positive (ALK+ve) large B-cell lymphoma * Plasmablastic lymphoma * Primary effusion lymphoma * Human herpesvirus 8 positive (HHV8+ve) DLBCL, NOS * High-grade B-cell lymphoma, with MYC and BCL2 and/or BCL6 rearrangements * High-grade B-cell lymphoma, NOS * B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and classical Hodgkin lymphoma * Intravascular large B-cell lymphoma * Primary effusion lymphoma